a safety review and meta-analyses of bevacizumab and ranibizumab off-label versus goldstandard安全审查和贝伐单抗和初标示外与goldstandard的荟萃分析.pdfVIP

a safety review and meta-analyses of bevacizumab and ranibizumab off-label versus goldstandard安全审查和贝伐单抗和初标示外与goldstandard的荟萃分析.pdf

  1. 1、有哪些信誉好的足球投注网站(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。。
  2. 2、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  3. 3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
  4. 4、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
  5. 5、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们
  6. 6、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
  7. 7、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
a safety review and meta-analyses of bevacizumab and ranibizumab off-label versus goldstandard安全审查和贝伐单抗和初标示外与goldstandard的荟萃分析

A Safety Review and Meta-Analyses of Bevacizumab and Ranibizumab: Off-Label versus Goldstandard 1 2 2 1 3 Christine Schmucker *, Christoph Ehlken , Hansjuergen T. Agostini , Gerd Antes , Gerta Ruecker , Monika Lelgemann4, Yoon K. Loke5 1 German Cochrane Institute, Institute of Medical Biometry and Medical Informatics, Department of Medical Biometry and Statistics, University Medical Centre Freiburg, Freiburg, Germany, 2 University Eye Hospital, University Medical Centre Freiburg, Freiburg, Germany, 3 Institute of Medical Biometry and Medical Informatics, Department of Medical Biometry and Statistics, University Medical Centre Freiburg, Freiburg, Germany, 4 Medical Advisory Service of the German Health Insurance Funds, Essen, Germany, 5 School of Medicine, University of East Anglia, Norwich, United Kingdom Abstract Background: We set out a systemic review to evaluate whether off-label bevacizumab is as safe as licensed ranibizumab, and whether bevacizumab can be justifiably offered to patients as a treatment for age-related macular degeneration with robust evidence of no differential risk. Methods and Findings: Medline, Embase and the Cochrane Library were searched with no limitations of language and year of publication. We included RCTs with a minimum follow-up of one year which investigated bevacizumab or ranibizumab in direct comparison or against any other control group (indirect comparison). Direct comparison (3 trials, 1333 patients): The one year data show a significantly higher rate of ocular adverse effects (AE) with bevacizumab compared to ranibizumab (RR = 2.8; 95% CI 1.2–6.5). The proportion of patients with serious infections and gastrointestinal disorders was also higher with bevacizumab than with ranibizu

您可能关注的文档

文档评论(0)

qianqiana + 关注
实名认证
文档贡献者

该用户很懒,什么也没介绍

版权声明书
用户编号:5132241303000003

1亿VIP精品文档

相关文档